"In May 2003, Easton led a $55.3 million financing for Acorda Therapeutics,
one of the top three private biotechnology financings to date in 2003. Easton's ability to lead
such a significant round, particularly in a challenging financial environment, is a testament to
its capabilities and excellence. Acorda's management and Board were thoroughly impressed by the
acumen and performance of the people at Easton. They comprise a rare mix of expertise in finance,
life sciences, business development and value creation, together with meticulous attention to detail
and passionate commitment. We are especially pleased that John Friedman has joined our Board of
Directors, where we expect his insights to contribute substantially to Acorda's future successes."
Ron Cohen
Founder, President, and CEO, Acorda Therapeutics
Xoft
Xoft is developing leading-edge new technologies for the practice of
radiation oncology through Electronic Brachytherapy, which utilizes
proprietary miniaturized x-ray tube technology. The Axxent(r) Electronic
Brachytherapy System, Xoft's first treatment system, is currently being
used in Accelerated Partial Breast Irradiation (APBI) for the treatment
of early-stage breast cancer. This solution provides a therapeutic dose
of intracavitary radiation directly to the region at risk without the
complex handling and resource logistics necessary when performing
brachytherapy using radioactive isotopes. Easton led an investment in
Xoft in March 2007. Other investors in the Company include MPM Capital,
Sutter Hill Ventures, Maverick Capital, Frazier Healthcare Ventures,
Mosaix Ventures, Cutlass Capital, RiverVest Venture Partners, Frantz
Medical Ventures, New Science Ventures and Hambrecht & Quist Capital
Management.